Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

VOS is potential game change in DES treatment

"The rapid onset and overall efficacy (as measured by the STT and FCS) demonstrated by VOS in this head-to-head study conducted against Restasis® is astounding and could be a game changer in the treatment landscape for dry eye," said Joseph Tauber, Principal Investigator of the study.

Above quote from: "Aurinia's Dry Eye Syndrome Drug Produces Mixed Results In Mid-Stage Trial".

https://www.benzinga.com/general/biotech/19/01/13015753/aurinias-dry-eye-syndrome-drug-produces-mixed-results-in-mid-stage-tr

IMO, not only were the VOS efficacy results "astounding", but so was the market reaction to it, albeit in a different way.